폐 환기의 과분극 ¹²⁹Xe 자기 공명 이미지 획득

Executive Industry Relevance

Hyperpolarized ¹²⁹Xe MRI enables spatially resolved, quantitative assessment of lung ventilation, addressing a critical gap in functional imaging for respiratory drug discovery and translational research. Standardized protocols and technical harmonization are essential for reproducible data generation across sites, supporting predictive confidence in preclinical and early clinical studies. This capability strengthens mechanistic de-risking and informs portfolio decisions in respiratory therapeutic development.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct visualization of regional lung ventilation defects for functional target validation.
• Supports biological de-risking by distinguishing disease-relevant ventilation patterns in preclinical models and patient cohorts.
• Facilitates predictive confidence in linking molecular interventions to functional respiratory outcomes.

Screening & Assay Development

• Provides a standardized imaging workflow for quantitative assessment of lung function in screening studies.
• Enables reproducible, site-independent assay outputs through harmonized technical parameters and dose preparation.
• Supports reliable evaluation of candidate interventions in disease-relevant systems.

Translational & Preclinical Research

• Aligns imaging endpoints with clinical biomarkers for translational continuity in respiratory research.
• Enables risk-adjusted advancement decisions by providing spatially resolved functional readouts in preclinical and early clinical settings.
• Supports mechanistic de-risking by correlating imaging findings with disease progression and therapeutic response.

Pipeline & Workflow Integration

Hyperpolarized ¹²⁹Xe MRI integrates into the discovery-to-translational continuum, bridging early target validation, screening, and preclinical efficacy assessment in respiratory portfolios.

• Discovery Biology: Supports hypothesis testing and pathway clarification by mapping functional lung defects to molecular targets.
• Screening: Delivers quantitative, reproducible imaging outputs for compound evaluation in disease models.
• Analytics: Provides spatially resolved, quantitative ventilation metrics for robust statistical comparison across conditions.
• Translational Research: Aligns imaging endpoints with clinical trial biomarkers, supporting seamless progression from preclinical to clinical studies.
• Enterprise Reuse: Establishes a standardized, scalable imaging platform for multi-site and multi-program deployment.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in respiratory drug development.
• Operational Value: Enables standardized, reproducible imaging workflows across research and clinical sites.
• Strategic Value: Improves go/no-go decision-making and capital efficiency by providing robust functional endpoints.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of respiratory assets.

Implementation Considerations

• Requires expertise in MR imaging physics and respiratory physiology for protocol optimization.
• Demands access to hyperpolarized ¹²⁹Xe gas, specialized coils, and MR-compatible monitoring equipment.
• Necessitates cross-team standardization of imaging parameters and safety monitoring procedures.
• Adaptation across different scanner platforms and subject populations may require protocol adjustments.
• Operational limitations include subject tolerability, technical training, and site readiness for standardized implementation.

Biopharma FAQs